Salarius Pharmaceuticals (SLRX) Competitors $0.78 0.00 (-0.04%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLRX vs. INDP, GNPX, AIM, CHRO, BFRI, ALBT, SNGX, AEZS, LIPO, and MTVAShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Indaptus Therapeutics (INDP), Genprex (GNPX), AIM ImmunoTech (AIM), Chromocell Therapeutics (CHRO), Biofrontera (BFRI), Avalon GloboCare (ALBT), Soligenix (SNGX), Aeterna Zentaris (AEZS), Lipella Pharmaceuticals (LIPO), and MetaVia (MTVA). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. Indaptus Therapeutics Genprex AIM ImmunoTech Chromocell Therapeutics Biofrontera Avalon GloboCare Soligenix Aeterna Zentaris Lipella Pharmaceuticals MetaVia Salarius Pharmaceuticals (NASDAQ:SLRX) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk. Do analysts prefer SLRX or INDP? Indaptus Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 2,136.84%. Given Indaptus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Indaptus Therapeutics is more favorable than Salarius Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Salarius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor SLRX or INDP? Salarius Pharmaceuticals received 13 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 86.67% of users gave Indaptus Therapeutics an outperform vote while only 54.17% of users gave Salarius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSalarius PharmaceuticalsOutperform Votes2654.17% Underperform Votes2245.83% Indaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33% Does the media favor SLRX or INDP? In the previous week, Salarius Pharmaceuticals' average media sentiment score of 3.00 beat Indaptus Therapeutics' score of 1.50 indicating that Salarius Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Salarius Pharmaceuticals Very Positive Indaptus Therapeutics Very Positive Is SLRX or INDP more profitable? Salarius Pharmaceuticals' return on equity of -140.28% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Salarius PharmaceuticalsN/A -140.28% -105.76% Indaptus Therapeutics N/A -177.27%-141.06% Which has higher valuation & earnings, SLRX or INDP? Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSalarius PharmaceuticalsN/AN/A-$12.54M-$4.82-0.16Indaptus TherapeuticsN/AN/A-$15.42M-$1.49-0.26 Do insiders & institutionals have more ownership in SLRX or INDP? 11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 1.4% of Salarius Pharmaceuticals shares are owned by company insiders. Comparatively, 29.5% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, SLRX or INDP? Salarius Pharmaceuticals has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. SummarySalarius Pharmaceuticals and Indaptus Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.67M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-0.108.9226.8419.71Price / SalesN/A250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book0.076.466.794.50Net Income-$12.54M$143.98M$3.23B$248.18M7 Day Performance-9.64%3.04%4.07%1.14%1 Month Performance13.90%7.44%12.52%15.20%1 Year Performance-79.14%-2.46%16.83%6.56% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals1.1815 of 5 stars$0.79+0.1%N/A-80.4%$1.67MN/A-0.1020Positive NewsEarnings ReportINDPIndaptus Therapeutics3.3477 of 5 stars$0.42+3.9%$8.50+1,941.8%-83.1%$6.68MN/A-0.246Earnings ReportGap DownGNPXGenprex0.9121 of 5 stars$0.28-3.3%$10.00+3,523.2%-88.2%$6.67MN/A0.0020Gap UpAIMAIM ImmunoTech1.444 of 5 stars$0.09-22.3%$2.75+2,908.8%-78.0%$6.61M$170,000.00-0.1920Gap DownHigh Trading VolumeCHROChromocell TherapeuticsN/A$1.08-1.9%N/A-43.4%$6.59MN/A-0.734Gap DownBFRIBiofrontera2.9023 of 5 stars$0.68-1.8%$7.00+925.6%-40.1%$6.45M$37.32M-0.3070Earnings ReportAnalyst ForecastAnalyst RevisionGap UpALBTAvalon GloboCare0.5526 of 5 stars$3.87-0.5%N/A-17.1%$6.39M$1.33M-0.195SNGXSoligenix0.9953 of 5 stars$1.96-1.3%N/A-68.0%$6.38M$840,000.00-0.2620Gap DownAEZSAeterna ZentarisN/A$3.55+5.0%N/A-57.9%$6.37M$2.37M-0.2420News CoverageAnalyst ForecastLIPOLipella Pharmaceuticals0.9453 of 5 stars$2.45+1.9%N/A-49.0%$6.23M$536,357.00-0.584Positive NewsEarnings ReportMTVAMetaVia1.8741 of 5 stars$0.70-3.9%$12.00+1,612.6%N/A$6.07MN/A0.008News CoverageEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies INDP Competitors GNPX Competitors AIM Competitors CHRO Competitors BFRI Competitors ALBT Competitors SNGX Competitors AEZS Competitors LIPO Competitors MTVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLRX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
